Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
for Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
15 locations incl. La Jolla
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT04895436·Phase 2·Recruiting